Description

Cytokinetics’ $23 Million MYQORZO Launch — Can Aficamten Become A Cardiology Powerhouse?

Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and positive clinical developments extending its cardiology pipeline. The company highlighted encouraging commercial momentum, with U.S. net product revenues from MYQORZO reaching $23 million and European launch initiation, particularly in Germany, contributing an additional $2.3 million. As of quarter-end, over 700 U.S. healthcare providers had prescribed MYQORZO, with more than 1,500 patients having received the drug, marking an approximate tripling from the first quarter. Patient and physician awareness increased, supported by robust digital marketing and scientific outreach activities. Payer access showed progress, with roughly 90% Medicare parity coverage and over 50% commercial coverage, on track for parity by the end of 2026. Clinical progress was underscored by positive top-line data from ACACIA-HCM, a pivotal Phase III trial evaluating aficamten in nonobstructive HCM (nHCM) patients—an area with no currently approved therapies.